WebDec 31, 2024 · Fourth Quarter 2024 Financial Results. For the three-month period ended Dec. 31, 2024, as compared to the same period of 2024 (where applicable): Total revenue was $473.8 million, an increase of 2 percent. Total revenue, excluding COVID-19 testing, increased 16 percent. Screening revenue was $277.7 million, an increase of 11 percent. WebExact Sciences Patient Hub
Alison Becker, BS Pharm - Director, Billing and ... - LinkedIn
WebExact Sciences was founded in 1995 to develop cancer screening methods, including DNA testing for colorectal cancer. Its Cologuard test received FDA approval in 2014 and in 2024 the company combined with Genomic Health to become leaders in global cancer diagnostics. It has recently acquired Thrive Earlier Detection Corp, in addition to Base ... WebAug 2, 2024 · Exact Sciences to take portion of initial payment in ... today announced it has entered into an asset purchase agreement with Genomic Health, Inc., a subsidiary of Exact Sciences ... BioPorto, Inc. and IQuity, Inc. He also formerly served on the board of directors of Exact Sciences Corporation (Nasdaq: EXAS) from May 2000, through its … short thick stick crossword clue
Exact Sciences Announces Third Quarter 2024 Results
WebPhysicianPortal. More than one million patients tested worldwide. Authentication. WebJul 29, 2024 · Exact Sciences and Genomic Health will address any questions regarding their earnings on the joint transaction call at 8 a.m. ET. Exact Sciences and Genomic Health have cancelled... WebNov 8, 2024 · Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company. Combined company joins two leading … short thick socks for boots